In last trading session, Protagonist Therapeutics Inc (NASDAQ:PTGX) saw 0.44 million shares changing hands with its beta currently measuring 2.12. Company’s recent per share price level of $33.39 trading at -$0.96 or -2.79% at ring of the bell on the day assigns it a market valuation of $1.96B. That closing price of PTGX’s stock is at a discount of -7.7% from its 52-week high price of $35.96 and is indicating a premium of 58.91% from its 52-week low price of $13.72. Taking a look at company’s average trading volume volume of 578.85K if we extend that period to 3-months.
Protagonist Therapeutics Inc (NASDAQ:PTGX) trade information
Upright in the red during last session for losing -2.79%, in the last five days PTGX remained trading in the red while hitting it’s week-highest on Wednesday, 06/12/24 when the stock touched $33.39 price level, adding 7.15% to its value on the day. Protagonist Therapeutics Inc’s shares saw a change of 45.62% in year-to-date performance and have moved -4.05% in past 5-day. Protagonist Therapeutics Inc (NASDAQ:PTGX) showed a performance of 6.10% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Protagonist Therapeutics Inc (PTGX) estimates and forecasts
Statistics highlight that Protagonist Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 64.08% of value to its shares in past 6 months, showing an annual growth rate of 220.14% while that of industry is 15.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.38% during past 5 years.
PTGX Dividends
Protagonist Therapeutics Inc is more likely to be releasing its next quarterly report in July and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
